Heron Therapeutics | HRTX - Ebit

Stock Price
1.20
Daily Change
-0.08 -5.91%
Monthly
-19.80%
Yearly
-28.01%
Q1 Forecast
2.71

Heron Therapeutics reported $-4.46M in EBIT for its fiscal quarter ending in September of 2024.





Ebit Change Date
ALKERMES USD 89.08M 3.9M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 34.85M Sep/2025
Amarin USD -1.7M 8.47M Sep/2025
ANI Pharmaceuticals USD 22.83M 7.66M Sep/2025
Anika Therapeutics USD -4.28M 3.58M Mar/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
Eisai JPY 20.03B 6.36B Dec/2025
Esperion Therapeutics USD -16.03M 11.51M Sep/2024
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Heron Therapeutics USD -4.46M 5.76M Sep/2024
Insmed USD -261.35M 7.48M Sep/2025
Ligand Pharmaceuticals USD 158.89M 115.32M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Nektar Therapeutics USD -34.34M 3.68M Sep/2024
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Omeros USD -48.15M 7.25M Sep/2023
Pacira USD 13.15M 2.92M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Surmodics USD -322K 2.13M Dec/2023
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Veracyte USD 23.11M 8.8M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025